Journey Resource Center

Filter:

Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes

December 1, 2016

Study

Early Progression of Diabetic Nephropathy Correlates With Methylglyoxal-Derived Advanced Glycation End Products

September 14, 2013

First Prev 1 2 3 Next Last

support@journeybio.life
(877) 618-1005

Home

Solution
Science

Company

Resources
Contact Us
Privacy Policy
Terms and Conditions

NaviDKD is a Lab Developed Test (LDT) developed and its performance characteristics were determined by Journey Biosciences. NaviDKD is performed in a CLIA certified laboratory and is intended for clinical purposes. NaviDKD has not been cleared by the US Food and Drug Administration. NaviDKD has been clinically validated and indicated for use as an aid to predict patients at risk for developing Diabetes-Related Kidney Disease (DKD) at a time in its development when appropriate preventative treatments can be initiated. NaviDKD is indicated for use in individuals 18 years of age or older diagnosed with Type 1, Type 2 or LADA diabetes.

Journey Resource Center

Filter:

Blogs

News

Studies

Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes

Early Progression of Diabetic Nephropathy Correlates With Methylglyoxal-Derived Advanced Glycation End Products